Lilly gears up for ‘unprecedented year,’ touts promising pipeline
Lilly gears up for ‘unprecedented year,’ touts promising pipeline Published: Jan 11, 2023 By Tristan Manalac BioSpace Following a banner year
Lilly gears up for ‘unprecedented year,’ touts promising pipeline Published: Jan 11, 2023 By Tristan Manalac BioSpace Following a banner year
Lilly plunks down up to $731M in GPCR pact with Sosei Published: Dec 16, 2022 By Tristan Manalac BioSpace Eli Lilly has entered into
Amgen says experimental obesity drug has promising durability By Deena Beasley LOS ANGELES, Dec 3 (Reuters) – Amgen Inc.’s (AMGN.O) experimental
FDA pulls U.S. authorization for Eli Lilly’s COVID drug bebtelovimab Nov 30 (Reuters) – Eli Lilly and Co’s COVID-19 drug bebtelovimab is not
With positive Phase II data, Nimbus’ psoriasis therapeutic poised to challenge BMS Published: Nov 30, 2022 By Mark Terry BioSpace Nimbus
Elon Musk's $44 billion bonfire continues to burn bright, with each new day bringing a new shitshow for our horrified amusement. The debacle du jour
Eli Lilly says some staff want to leave Indiana because of abortion ban, Financial Times reports Nov 6 (Reuters) – Some Eli Lilly and
Lilly, Boehringer say Jardiance slows kidney disease progression in trial FRANKFURT, Nov 4 (Reuters) – Boehringer Ingelheim and Eli
Eli Lilly’s bleak annual forecast overshadows quarterly beat Nov 1 (Reuters) – Eli Lilly and Co. (LLY.N) on Tuesday forecast its annual profit
Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research
On Monday at the Emerson Exchange Users’ Conference, Emerson’s Michalle Adkins and AbbVie’s Jeff Ziolkowski moderated a panel with
Pfizer and Erasca target pancreatic, colorectal cancer with “synergistic” pairing Published: Oct 20, 2022 By Tristan
New research unveiled Monday estimates that around 1.3 million U.S. adults with diabetes either skipped entire insulin doses, took less than needed,
Eli Lilly bets nearly $500M on metabolic disease pact with Nimbus Published: Oct 12, 2022 By Alex Keown BioSpace Nimbus Therapeutics scored a $496
PureTech and Nektar call off rumored merger Published: Oct 11, 2022 By Mark Terry BioSpace Last week, rumors spread that PureTech Health was